Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 06, 2025 16:00 ET | Source: Arcutis Biotherapeutics, Inc.

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WESTLAKE VILLAGE, Calif., June 06, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in...
June 06, 2025 08:00 ET | Source: Arcutis Biotherapeutics, Inc.

Arcutis to Present New Long-Term Results of ZORYVE® (roflumilast) Cream at the 2025 Revolutionizing Atopic Dermatitis Conference

Arcutis to present five posters at the 2025 Revolutionizing Atopic Dermatitis (RAD) Conference, taking place in Nashville, TN, from June 6-7, 2025.
May 29, 2025 16:00 ET | Source: Arcutis Biotherapeutics, Inc.

Arcutis to Present at the Goldman Sachs 46th Annual Global Healthcare Conference

Arcutis today announced that management will participate in the Goldman Sachs 46th Annual Global Healthcare Conference, taking place June 9-11, 2025.
May 22, 2025 14:12 ET | Source: Arcutis Biotherapeutics, Inc.

Arcutis’ ZORYVE® (roflumilast) Topical Foam 0.3% Approved by U.S. FDA for the Treatment of Plaque Psoriasis in Adults and Adolescents Ages 12 and Older

FDA has approved the supplemental New Drug Application (sNDA) for ZORYVE® foam 0.3% for the treatment of plaque psoriasis
May 15, 2025 09:29 ET | Source: Arcutis Biotherapeutics, Inc.

New Consensus Statements on Impact of Genital Psoriasis on Patients from Genital Psoriasis Wellness Consortium Published in Journal of the European Academy of Dermatology and Venereology Clinical Practice

Arcutis announced the publication of 14 consensus statements from the Genital Psoriasis Wellness Consortium on the impact of genital psoriasis on patients.
May 07, 2025 11:18 ET | Source: Arcutis Biotherapeutics, Inc.

Arcutis Announces Publication of Positive Data from ARRECTOR Trial Evaluating ZORYVE® (roflumilast) Foam 0.3% in Individuals with Psoriasis in Journal of American Medical Association Dermatology

JAMA Dermatology published the positive results from a pivotal Phase 3 study evaluating the efficacy and safety of ZORYVE® (roflumilast) foam 0.3%
May 06, 2025 16:00 ET | Source: Arcutis Biotherapeutics, Inc.

Arcutis Announces First Quarter 2025 Financial Results and Provides Business Update

Arcutis today reported financial results for the quarter ended March 31, 2025, and provided a business update.
May 02, 2025 16:00 ET | Source: Arcutis Biotherapeutics, Inc.

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WESTLAKE VILLAGE, Calif., May 02, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in...
April 17, 2025 08:00 ET | Source: Arcutis Biotherapeutics, Inc.

Arcutis to Report First Quarter 2025 Financial Results and Host Conference Call on May 6, 2025

Arcutis today announced that it will report Q1'25 financial results and provide a business update on May 6, 2025 after the U.S. financial markets close.
April 10, 2025 16:30 ET | Source: Arcutis Biotherapeutics, Inc.

Arcutis Announces Chief Financial Officer Transition

WESTLAKE VILLAGE, Calif., April 10, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations...